Skip to main content
Premium Trial:

Request an Annual Quote

BioSeek Expands Plan to Screen Compounds for UCB

NEW YORK (GenomeWeb News) — BioSeek said today that it has renewed and expanded an agreement to profile and guide optimization of lead compounds for the drug company UCB.
 
South San Francisco, Calif.-based BioSeek said it will profile selected chemical and biological entities and guide lead optimization of a specific phenotypic hit identified by UCB and characterized using the company’s BioMap screens.
 
Under the one-year agreement, which expands a 2007 pact, BioSeek will receive an up-front licensing fee, funding for research, and both clinical and preclinical milestone payments based on candidate advancement using the BioMap platform.
 
The BioMap System uses predictive human cell-based models to generate activity profiles of potential drug candidates.
 
“Our 2007 collaboration identified specific areas of high interest to UCB where the BioMap platform could be productively applied to UCB projects, and those form the basis of the new agreement encompassing two major programs in bioactive annotation and lead optimization,” BioSeek CEO Michael Venuti said in a statement. “By focusing on pharmacological outcome in a defined set of validated human cell-based screens, novel bioactivity can be detected, and anecdotally observed activity can be optimized.”
 
UCB’s primary focus is on developing drugs to treat central nervous system disorders, inflammation, and cancer.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.